Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | MRK | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 89.65 | 0.00 | 0.00 | 0.00 | 89.65 | 19:00:00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Merck Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 228.25B | 2.55B | $ 6.22B | 2.32 | 25.50 | 2.54B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 25.15M | $ 1.99 | 2.22% | 12/13/19 | - | - |
Merck News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 91.97 | 92.0554 | 89.52 | 90.44 | 8,386,956 | -2.32 | -2.52% |
| 1 Month | 91.60 | 92.44 | 88.40 | 90.25 | 7,550,558 | -1.95 | -2.13% |
| 3 Months | 86.31 | 92.64 | 82.50 | 87.94 | 7,980,183 | 3.34 | 3.87% |
| 6 Months | 81.05 | 92.64 | 78.85 | 85.67 | 8,218,869 | 8.60 | 10.61% |
| 1 Year | 75.55 | 92.64 | 72.05 | 82.40 | 9,396,005 | 14.10 | 18.66% |
| 3 Years | 61.81 | 92.64 | 52.83 | 69.72 | 9,587,027 | 27.84 | 45.04% |
| 5 Years | 62.46 | 92.64 | 45.69 | 64.62 | 9,520,176 | 27.19 | 43.53% |
Merck Description
| Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States. |
